Name and surname:
|
prof. MUDr. Danka Švecová, PhD.
|
Document type:
|
Research/art/teacher profile of a person
|
The name of the university:
|
Comenius University Bratislava
|
The seat of the university:
|
Šafárikovo námestie 6, 818 06 Bratislava
|
III.a - Occupation-position | III.b - Institution | III.c - Duration |
---|---|---|
University teacher- Assistant Professor- Assistant specialist Professor- Associate Professor - University Professor | Faculty of Medicine Comenius University in Bratislava | 1979 - continue |
Professor of Dermatology | University Hospital Old Town of Comenius University in Bratislava | 1979- continue |
IV.a - Activity description, course name, other | IV.b - Name of the institution | IV.c - Year |
---|---|---|
Specialization of second degree Dermatology | Institute of Further Education of Physicians and Pharmacists in Prague, Czech Republic | 1991 |
Specialization of first degree Dermatology | Institute of Further Education of Physicians and Pharmacists in Bratislava, Slovak Republic | 1982 |
Study stay in Dermatology "Skin and Allergy" | Hokkaido University School of Medicine, Sapporo, Japan | 1996 |
Study stay in Dermatovenerology for Specialization of second Degree | Institute of Further Education of Physicians and Pharmacists in Prague, Czech Republic | 1991 |
Royal Holloway University of London, U.K. | The International Conference on Harmonisation - Good Clinical Practice Guide Course | 2014 |
The Investigator Site personnel ICH GCP Training Certtificate - Good Clinical Practice | Transcelerate Biopharma, Inc, Pennsylvania, USA | 2018 |
European computer driver licence Start-up, sylabus version: 4.0 2008 | Comenius University in Bratislava | 2008 |
Microsoft Innovative Educator: Command Expert of the TEAMS | Comenius University in Bratislava | 2020 |
Microsoft Innovative Educator: Command Expert of the PowerPoint | Comenius University in Bratislava | 2023 |
V.1.a - Name of the profile course | V.1.b - Study programme | V.1.c - Degree | V.1.d - Field of study |
---|---|---|---|
Dermatovenerology 1+2 in slovak and english languages. Course ID: LF.DK/L-S-VL-008/19 | General Medicine | I. II | General Medicine |
Dermatovenerology in slovak and english languages. Course ID: LF.DK/L-ZLa-018/20 | Dentistry | I. II. | Dentistry |
Completition of the compulsory subject "New Trends in Dermatovenerology". Course ID: LF/L-PhD-007/22 | General Medicine | III. | General Medicine |
V.2.a - Name of the study programme | V.2.b - Degree | V.2.c - Field of study |
---|---|---|
Dermatovenerology. Specialization study | III. | General Medicine |
Švecová D, Lubell MW, Casset-Semanaz F, Mackenzie H, Grenningloh R, Krueger J. A randomized, double-blind, placebo-controlled phase I study of mutiple ascending doses of subcutaneous M1095, an anti-interleukin 17 A/F nanobody, in moderate-to-severe psoriasis. Journal of American Academy of Dermatology. 2019; 81:196-203. (Q1, IF=8.277)
Javor J, Chmúová N, Parnická Z, Ferenčík S, Grosse-Wilde H, Buc M, Švecová D.
TNF-alpha and IL-10 gene polymorphisms show a weak association with pemphigus vulgarisin the Slovak population. Journal of European Academy of Dermatology and Venereology. 2010;24:65-68. (Q1, IF=3.309)
Sochorova R, Švecova D, Sinka L, Rybarova L.
Increased endothelemia as an indirect marker of changes in the blood vessel endothelium in psoriasis. Journal of European Academy of Dermatology annd Venereology 2004; 18 (5): 556-559 (Q2, IF=1,401).
Švecová D. Pemphigus vulgaris: a clinical study of 44 cases over a 20-year period.International Journal of Dermatology. 2015; 54:1138-1144.(Q3, IF=1.415)
Švecová D, Párnická Z, Pastyriková L, Urbanček S, Luha J, Buc M.
HLA DRB1* and DQB1* alleles are associated with disease severity in patients with pemphigus vulgaris. International Journal of Dermatology. 2015; 54:168-173. (Q3, IF=1.415).
Švecová D, Lubell MW, Casset-Semanaz F, Mackenzie H, Grenningloh R, Krueger J. A randomized, double-blind, placebo-controlled phase I study of mutiple ascending doses of subcutaneous M1095, an anti-interleukin 17 A/F nanobody, in moderate-to-severe psoriasis. Journal of American Academy of Dermatology. 2019; 81:196-203. (Q1, IF=8.277)
Svecová D, Nemsovska J, Babal P. Clinical manifestation variability of bullous pemphigoid. Bratislava Medical Journal 2024; 125 (11):685-692. (Q2, IF 1.5).
Nemšovská J, Waczulíková I, Švecová D.Basophil activation in the diagnostics of hymmenoptera venon allergy. Bratislava Medical Journal 2021;122 (11):778-784. (Q2, IF 1.564).
Paul C, Stratigos Aj, Nijsten T et al. Author members: Svecova D et al. The "Buder of skin diseases" project: a population-based study on 44,689 Participants from 27 European countries. Minerva Medica. 2025; 116(1):81-83. (Q1, IF=4,7).
Švecová D. Pemphigus vulgaris: a clinical study of 44 cases over a 20-year period.International Journal of Dermatology. 2015; 54:1138-1144.(Q3, IF=1.415)
Papp KA, Weinberg MA, Morris A, Reich K. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlelled , phase 2b study. The Lancet, 2021; 397:1564-1575 (Q1, IF=79,321).
Cheng L, Zhang X, Chen Y et all. Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients. Signal Trasduction and Targeted Therapy. 2021;6:304.(Q1, F=18,187).
Prinz I, Sandrock I, Mrowietz U. Effectors and targets in psoriasis - a breakthrough in understanding and treatment. Journal of Experimental Medicine. 2020; 217: e20191397 (Q1, IF=14,307).
Strober B, Carle P, Andrew B et all. Bimekizumab efficacy and safet& in patients with moderate to severe plaque psoriasis: two year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. Journal of the American Academy of Dermatology. 2023; 89(3):486-495. (Q1, IF=11.5)
Assaf S, Malki L, Mayer T et al. ST18 affects cell–cell adhesion in pemphigus vulgaris in a tumour necrosis factor‐α‐dependent fashion. British Journal of Dermatology. 2021; 184(6):1153-1160.(Q1, IF=11,113).
Clinical study a phase I: Multicentre, phase I, randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics and efficacy of multiple ascending doses of subcutaneous MSB0010841 (anti-IL17A/F nanobody) in male and female subjects with moderate to severe psoriasis. EudraCT:2013-005436-18.
Principal Investigator and Principal European Coordinator.
Publication:
Švecová D, Lubell MW, Casset-Semanaz F, Mackenzie H, Grenningloh R, Krueger J. A randomized, double-blind, placebo-controlled phase I study of mutiple ascending doses of subcutaneous M1095, an anti-interleukin 17 A/F nanobody, in moderate-to-severe psoriasis. Journal of American Academy of Dermatology 2019; 81:196-203. (Q1, IF=8,177).
Clinical study a phase I: A phase 1, double-blind randomized, placebo controlled, multi dose study to evaluate the safety, tolerability, and pharmacokinetics of subcutaneous LY3361237 in participants with psoriasis. EudraCT:2019-003187-40.
Principal Inverstigator.
Clinical study a phase III: A phase 3 randomized, double-blind, double-dummy, placebo-controlled, parallel group, multi-center study investigating the efficacy and safety of PF-04965842 and dupilumab in comparison with placebo in adult subjects on background topical therapy, with moderate to severe atopic dermatitis. B7451029, IND 123554. EudraCT Number 2018-002573-21.
Principal Investigator.
Publication:
Bieber T, Simpson J, Siverberg D et al. JADE COMPARE Investigators : Svecova D et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. New England Journal of Medicine 2021;384: 1101-1012. (Q1, IF=74,699).
Clinical study a phase II/III: A phase 2/3, randomized, double-blinded, placebo-controlled, parallel-group study to investigate the efficacy and safety of efgartigimod PH20SC in adut participants with bullous pemphigoid. Protocol number ARGX-113-2009. IND:1555276. EudraCT: 2021-003087-27.
Principal Investigator.
VEGA 1/7359/20: Immunomodulatory and antiinflamatory efficacy of natural phenols. In cooperation with Faculty of Pharmacy Coemnius University in Bratislava.
Vice- Investigator.
Publication:
Hajnická V, Košťálová D, Švecová D, Sochorová R, Fuchsberger N, Tóth J. Effect of Mahonia aquifolium active compounds on interleukin-8 production in the human monocytic cell line THP-1. Planta Medica 2002; 68: 266-268. (Q1, IF=2,289)
Clinical study phase II/III: An Open-label Extension Study of ARGX-1132009 to Evaluate the long-term safety, tolerability of efgartigimod PH20 SC in adut participants with bullous pemphigoid. Protocol number ARGX-113-2010. EudraCT: 2021-003063-10.
Principal investigator
VII.a - Activity, position | VII.b - Name of the institution, board | VII.c - Duration |
---|---|---|
23rd Asia-pacific Dermatology Conference,Osaka, Japan, Organisation Committee member | Conferenceserie.com., Delaware , USA | October 26.- 28. 2017 |
7th International Conferecnce on Family medicine & Primary care, Paris, France, Organisation Committee member | CEO, EuroSciCon, UK | February 22. - 24. 2018 |
17th European Dermatology Congress, Paris, France, Organisation Committee member | Conferenceseries.com, London, UK | March 1. - 3. 2018 |
VIII.a - Name of the institution | VIII.b - Address of the institution | VIII.c - Duration (indicate the duration of stay) | VIII.d - Mobility scheme, employment contract, other (describe) |
---|---|---|---|
Hokkaido Universirty School of Medicine | Sapporo, Japan | 8. July 1996 - 30. September 1996 | Under the supervision of Professor Akira Ohkawara, Dermatology "Alergy and Skin" |
Institute of Further Education of Physicians and Pharmacists in Prague, Czech Republic | University Hospital Bulovka, Prague 8, Czech Republic | 1. April 1991- 25. June 1991 | Under the supervision of Associate professor Pavel Barták, CsC. |
2023 - continue Co-garant for the Dizertation Doktorand Study in Dermatovenerology, Faculty of Medicine Comenius University in Bratislava
2012 - continue Member of the Committee for Dizertation Doktorand Study in Dermatovenerology, Faculty of Medicine Comenius University in Bratislava
2009 - continue Member of the Committee for Specialization in Dermatovenerology, Faculty of Medicine Comenius University in Bratislava
2009 - continue Member of the Committee for Specialization in Dermatovenerology, University of Pavel Jozef Šafarik, Košice
2005-2012- Member of the Committee for Dizertation Doktorand Study in Imunology, Faculty of Medicine Comenius University in Bratislava
2011- continue Member of the committee for the State Conclusive Exam for General Medicine in slovak and english languages,
Faculty of Medicine Comenius University in Bratislava
2011- Gold Award, e-poster, World Congress of Dermatology, Seoul, South Korea
2011- continue Rewiever of scientific publications in Current Content Journals: Journal of European Academy of Dermatology and Venereology, International Journal of Dermatology,Journal of Immunology Research, Hindawi Portfolio of Journals, Archives of Dermatological Research (Springer Nature), Scientific Reports (Springer Nature), Bratislava Medical Journal (Springer Nature)